357 related articles for article (PubMed ID: 21214408)
21. Phenotyping and Target Expression Profiling of CD34
Blatt K; Menzl I; Eisenwort G; Cerny-Reiterer S; Herrmann H; Herndlhofer S; Stefanzl G; Sadovnik I; Berger D; Keller A; Hauswirth A; Hoermann G; Willmann M; Rülicke T; Sill H; Sperr WR; Mannhalter C; Melo JV; Jäger U; Sexl V; Valent P
Neoplasia; 2018 Jun; 20(6):632-642. PubMed ID: 29772458
[TBL] [Abstract][Full Text] [Related]
22. [The immunophenotypic analysis of CD7+ and (or) CD56+ acute myeloid leukemic stem cells and its applications in minimal residual disease detection].
Cao H; Wang YZ; Wu HH; Chang Y; Hao L; Chen SS; Huang XJ; Lu DP; Liu YR
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):23-8. PubMed ID: 18512311
[TBL] [Abstract][Full Text] [Related]
23. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.
Vergez F; Green AS; Tamburini J; Sarry JE; Gaillard B; Cornillet-Lefebvre P; Pannetier M; Neyret A; Chapuis N; Ifrah N; Dreyfus F; Manenti S; Demur C; Delabesse E; Lacombe C; Mayeux P; Bouscary D; Recher C; Bardet V
Haematologica; 2011 Dec; 96(12):1792-8. PubMed ID: 21933861
[TBL] [Abstract][Full Text] [Related]
24. The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse.
Bachas C; Schuurhuis GJ; Assaraf YG; Kwidama ZJ; Kelder A; Wouters F; Snel AN; Kaspers GJ; Cloos J
Leukemia; 2012 Jun; 26(6):1313-20. PubMed ID: 22289983
[TBL] [Abstract][Full Text] [Related]
25. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
[TBL] [Abstract][Full Text] [Related]
26. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells.
Ito S; Barrett AJ; Dutra A; Pak E; Miner S; Keyvanfar K; Hensel NF; Rezvani K; Muranski P; Liu P; Larochelle A; Melenhorst JJ
Stem Cell Res; 2015 Jan; 14(1):95-104. PubMed ID: 25535865
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation.
Jentzsch M; Bill M; Nicolet D; Leiblein S; Schubert K; Pless M; Bergmann U; Wildenberger K; Schuhmann L; Cross M; Pönisch W; Franke GN; Vucinic V; Lange T; Behre G; Mrózek K; Bloomfield CD; Niederwieser D; Schwind S
Am J Hematol; 2017 Apr; 92(4):388-396. PubMed ID: 28133783
[TBL] [Abstract][Full Text] [Related]
28. The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors.
Costello R; Mallet F; Chambost H; Sainty D; Arnoulet C; Gastaut JA; Olive D
Leukemia; 1999 Oct; 13(10):1513-8. PubMed ID: 10516751
[TBL] [Abstract][Full Text] [Related]
29. CD34
Zeijlemaker W; Grob T; Meijer R; Hanekamp D; Kelder A; Carbaat-Ham JC; Oussoren-Brockhoff YJM; Snel AN; Veldhuizen D; Scholten WJ; Maertens J; Breems DA; Pabst T; Manz MG; van der Velden VHJ; Slomp J; Preijers F; Cloos J; van de Loosdrecht AA; Löwenberg B; Valk PJM; Jongen-Lavrencic M; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2019 May; 33(5):1102-1112. PubMed ID: 30542144
[TBL] [Abstract][Full Text] [Related]
30. Higher percentage of CD34 + CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia.
Plesa A; Elhamri M; Clapisson G; Mattei E; Gazzo S; Hequet O; Tigaud I; Michallet M; Dumontet C; Thomas X
Leuk Lymphoma; 2015 Mar; 56(3):622-9. PubMed ID: 24884314
[TBL] [Abstract][Full Text] [Related]
31. CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells.
Touzet L; Dumezy F; Roumier C; Berthon C; Bories C; Quesnel B; Preudhomme C; Boyer T
Cancer Med; 2019 Mar; 8(3):1279-1288. PubMed ID: 30740913
[TBL] [Abstract][Full Text] [Related]
32. High proportion of CD34+/CD38-cells is positively correlated with poor prognosis in newly diagnosed childhood acute lymphoblastic leukemia.
Long J; Liu S; Li K; Zhou X; Zhang P; Zou L
Leuk Lymphoma; 2014 Mar; 55(3):611-7. PubMed ID: 23706103
[TBL] [Abstract][Full Text] [Related]
33. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
Herrmann H; Blatt K; Shi J; Gleixner KV; Cerny-Reiterer S; Müllauer L; Vakoc CR; Sperr WR; Horny HP; Bradner JE; Zuber J; Valent P
Oncotarget; 2012 Dec; 3(12):1588-99. PubMed ID: 23249862
[TBL] [Abstract][Full Text] [Related]
34. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P
Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666
[TBL] [Abstract][Full Text] [Related]
35. [Characteristic and prognostic significance of leukemia stem cells associated antigens expressions in t (8;21) acute myeloid leukemia].
Dao FT; Yang L; Wang YZ; Chang Y; Jiang Q; Jiang H; Liu YR; Huang XJ; Qin YZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):831-836. PubMed ID: 31775482
[No Abstract] [Full Text] [Related]
36. Lower phosphorylation of p38 MAPK blocks the oxidative stress-induced senescence in myeloid leukemic CD34(+)CD38 (-) cells.
Xiao Y; Zou P; Wang J; Song H; Zou J; Liu L
J Huazhong Univ Sci Technolog Med Sci; 2012 Jun; 32(3):328-333. PubMed ID: 22684553
[TBL] [Abstract][Full Text] [Related]
37. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
38. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
[TBL] [Abstract][Full Text] [Related]
39. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
Roug AS; Larsen HØ; Nederby L; Just T; Brown G; Nyvold CG; Ommen HB; Hokland P
Br J Haematol; 2014 Jan; 164(2):212-22. PubMed ID: 24152218
[TBL] [Abstract][Full Text] [Related]
40. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.
Garg S; Shanmukhaiah C; Marathe S; Mishra P; Babu Rao V; Ghosh K; Madkaikar M
Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
